ALX's conjugate foray goes clinical
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Novel cadherin conjugates enter the clinic
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
Boehringer slims down in SIRPα
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
